Edavarone as a treatment for HHV-6
Changes in cerebrospinal fluid biomarkers in human herpesvirus-6-associated acute encephalopathy/febrile seizures.
http://www.ncbi.nlm.nih.gov/pubmed/25294958
Abstract
To
determine the involvement of oxidative stress in the pathogenesis of
acute encephalopathy associated with human herpesvirus-6 (HHV-6)
infection, we measured the levels of oxidative stress markers
8-hydroxy-2'-deoxyguanosine (8-OHdG) and hexanoyl-lysine adduct (HEL),
tau protein, and cytokines in cerebrospinal fluid (CSF) obtained from
patients with HHV-6-associated acute encephalopathy (HHV-6
encephalopathy) (n = 16) and complex febrile seizures associated with
HHV-6 (HHV-6 complex FS) (n = 10). We also examined changes in CSF-8OHdG
and CSF-HEL levels in patients with HHV-6 encephalopathy before and
after treatment with edaravone, a free radical scavenger. CSF-8-OHdG
levels in HHV-6 encephalopathy and HHV-6 complex FS were significantly
higher than in control subjects. In contrast, CSF-HEL levels showed no
significant difference between groups. The levels of total tau protein
in HHV-6 encephalopathy were significantly higher than in control
subjects. In six patients with HHV-6 infection (5 encephalopathy and 1
febrile seizure), the CSF-8-OHdG levels of five patients decreased after
edaravone treatment. Our results suggest that oxidative DNA damage is
involved in acute encephalopathy associated with HHV-6 infection.
Edaravone (Radicut) is a neuroprotective agent used for the purpose of aiding neurological recovery following acute brain ischemia and subsequent cerebral infarction.[1] It acts as a potent antioxidant and strongly scavenges free radicals, protecting against oxidative stress and neuronal apoptosis.[2][3][4] It has been marketed solely in Japan by Mitsubishi Pharma since 2001.[1] and marketed in India by Edinburgh Pharmaceuticals by the brand name Arone
Edaravone has been shown to attenuate methamphetamine- and 6-OHDA-induced dopaminergic neurotoxicity in the striatum and substantia nigra, and does not affect methamphetamine-induced dopamine release or hyperthermia.[5][6] It has also been demonstrated to protect against MPTP-mediated dopaminergic neurotoxicity to the substantia nigra, though notably not to the striatum.[7][8][9]
Edaravone
From Wikipedia, the free encyclopedia
Edaravone (Radicut) is a neuroprotective agent used for the purpose of aiding neurological recovery following acute brain ischemia and subsequent cerebral infarction.[1] It acts as a potent antioxidant and strongly scavenges free radicals, protecting against oxidative stress and neuronal apoptosis.[2][3][4] It has been marketed solely in Japan by Mitsubishi Pharma since 2001.[1] and marketed in India by Edinburgh Pharmaceuticals by the brand name Arone
Edaravone has been shown to attenuate methamphetamine- and 6-OHDA-induced dopaminergic neurotoxicity in the striatum and substantia nigra, and does not affect methamphetamine-induced dopamine release or hyperthermia.[5][6] It has also been demonstrated to protect against MPTP-mediated dopaminergic neurotoxicity to the substantia nigra, though notably not to the striatum.[7][8][9]